2 active not recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
Follow CP protocol: new trials by email Literature Review of CP protocol trials Research Report on CP protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer Drug: Anlotinib, Drug: Carboplatin/Paclitaxel - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Active not recruiting | Wenjun Cheng | 56 | 2021-08-24 | 2024-07-03 |
| Adjuvant Palbociclib in Elderly Patients With Breast Cancer Palbociclib, Docetaxel / cyclophosphamide, doxorubicin/cyclophosphamide - Breast Cancer Stage II, Breast Cancer Stage III | Phase 2 | Active not recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 366 | 2019-06-14 | 2026-05-12 |
Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Ovarian Epithelial (1) · Endocrine System Diseases (1) · Fallopian Tube Neoplasms (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Ovarian Diseases (1) · Ovarian Neoplasms (1)
European Organisation for Research and Treatment of Cancer - EORTC (1) · Wenjun Cheng (1)
Belgium (1) · China (1) · France (1) · Germany (1) · Italy (1) · Jordan (1) · Poland (1) · Portugal (1) · Spain (1) · United Kingdom (1)
Hans Wildiers, MD, PhD (1) · Wenjun Cheng, MD,PhD (1)